Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback